Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Taladegib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Endeavor Bio Granted EMA PRIME Designation For Taladegib
    Endeavor Bio Granted EMA PRIME Designation For Taladegib

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103520715/en/Endeavor-BioMedicines-Receives-Priority-Medicines-PRIME-Designation-from-the-European-Medicines-Agency-for-Taladegib-ENV-101-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Endeavor Biomedicines Releases Positive Phase 2a Data
    Endeavor Biomedicines Releases Positive Phase 2a Data

    30 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929248127/en/Endeavor-BioMedicines-Announces-Publication-of-Positive-Data-from-Phase-2a-Trial-in-The-Lancet-Respiratory-Medicine-Evaluating-taladegib-ENV-101-in-Individuals-with-Idiopathic-Pulmonary-Fibrosis

    BUSINESSWIRE
    30 Sep 2025
    Share Share
    Endeavor Bio' Ph 2a Taladegib Results at ERS Congress 2025
    Endeavor Bio' Ph 2a Taladegib Results at ERS Congress 2025

    10 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-10/endeavor-biomedicines-to-present-results-from-phase-2a-trial-of-taladegib-env-101-in-an-alert-sess

    PHARMAWEB
    10 Sep 2025
    Share Share
    Endeavor BioMedicines Names ILD Expert Lisa Lancaster CMO
    Endeavor BioMedicines Names ILD Expert Lisa Lancaster CMO

    02 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250402562765/en/Endeavor-BioMedicines-Appoints-Internationally-Renowned-ILD-Expert-Lisa-Lancaster-M.D.-as-Chief-Medical-Officer

    BUSINESSWIRE
    02 Apr 2025
    Share Share
    Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101
    Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101

    06 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230906375636/en

    BUSINESSWIRE
    06 Sep 2023
    Share Share
    Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)
    Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)

    25 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220525005283/en

    BUSINESSWIRE
    25 May 2022
    Share Share